Genolution Inc is a Korea-based company principally engaged in the manufacture and distribution of molecular diagnostic equipment and products related to ribonucleic acid interference (RNAi) research. The Company is mainly engaged in the manufacture and sales of nucleic acid extraction reagents for extracting nucleic acids from human samples and automated nucleic acid extraction devices for automatically extracting nucleic acids from samples. The Company also provides RNAi services. The Company distributes its products within domestic market and to overseas markets.

Employees

Sector

Biotechnology & Medical Research

More about the company

Quotes

Date	Price	Change	Volume
26-07-16	₩1,357.00	-0.07%	30,835
26-07-15	₩1,358.00	0.00%	35,013
26-07-14	₩1,358.00	-2.51%	123,088
26-07-13	₩1,393.00	+0.58%	48,720
26-07-10	₩1,385.00	+1.84%	51,776

End-of-day quote Korea S.E.

More quotes

Income Statement and Estimates

More financial data

Select your edition

All financial news and data tailored to specific country editions

NORTH AMERICA

United-States

Canada

End-of-day quote Korea S.E. Other stock markets 2026-07-16			5-day change	1st Jan Change
1,357.00 ^KRW	-0.07%		-2.02%	-28.54%

02-18	Kim Ki-ok completed the acquisition of 4.22% stake in Genolution Inc. from HoilBioMed Co., Ltd.	CI
01-20	Kim Ki-ok agreed to acquire 4.22% stake in Genolution Inc. from HoilBioMed Co., Ltd for KRW 1.5 billion.	CI

Market Cap	24.52B 16.49M 14.41M 13.3M 12.26M 23.1M 1.59B 23.61M 159M 62.5M 778M 61.92M 60.56M 2.68B	P/E 2024	-5.89x	P/E 2025	-2.95x
Enterprise Value	20.63B 13.87M 12.12M 11.19M 10.31M 19.44M 1.34B 19.87M 134M 52.6M 654M 52.1M 50.96M 2.25B	EV / Sales 2024	4.38x	EV / Sales 2025	3.23x
Free-Float	67.03%	Yield 2024 *	-	Yield 2025	-

02-18	Kim Ki-ok completed the acquisition of 4.22% stake in Genolution Inc. from HoilBioMed Co., Ltd.	CI
01-20	Kim Ki-ok agreed to acquire 4.22% stake in Genolution Inc. from HoilBioMed Co., Ltd for KRW 1.5 billion.	CI
24-07-30	Genolution Inc. cancelled the transaction announced on May 7, 2024	CI
24-05-06	Genolution Inc. announced that it expects to receive CNY 750.00284 million in funding from RICO Asset Management Co., Ltd. and another investor	CI
24-01-09	Tranche Update on Genolution Inc.'s Equity Buyback Plan announced on July 10, 2023.	CI
24-01-09	Tranche Update on Genolution Inc.'s Equity Buyback Plan announced on July 10, 2023.	CI
24-01-08	Genolution Inc.'s Equity Buyback announced on July 10, 2023, has expired with 477,003 shares, representing 2.59% for KRW 1,989.17 million.	CI
23-10-13	Tranche Update on Genolution Inc.'s Equity Buyback Plan announced on July 10, 2023.	CI
23-07-10	Genolution Inc. announces an Equity Buyback for KRW 2,000 million worth of its shares.	CI
23-07-09	Genolution Inc. authorizes a Buyback Plan.	CI
23-05-15	Genolution Inc. Reports Earnings Results for the First Quarter Ended March 31, 2023	CI
23-04-05	Tranche Update on Genolution Inc.'s Equity Buyback Plan announced on October 6, 2022.	CI
23-04-05	Tranche Update on Genolution Inc.'s Equity Buyback Plan announced on October 6, 2022.	CI

1 day	-0.07%
1 week	-2.02%
Current month	+12.15%
1 month	-7.25%
3 months	-33.64%
6 months	-27.82%
Current year	-28.54%

Genolution Inc. Stock

Stocks

A225220

KR7225220003

Biotechnology & Medical Research

Valuation: Genolution Inc.

Chart: Genolution Inc.

Latest news : Genolution Inc.

Quotes and Performance

Course Extremes

Managers and Directors: Genolution Inc.

Latest insider transactions

Bio Diagnostics & Testing

Financials

Company Profile

Quotes

Income Statement and Estimates

1 week	1,300	1,415
1 month	957	1,458
Current year	957	2,120
1 year	957	2,830
3 years	957	5,140
5 years	957	9,455.45
10 years	957	13,118.81

Manager	Title	Age	Since
Min-Ee Kim CEO	Chief Executive Officer	40	-
Ki-Ok Kim CEO	Chief Executive Officer	71	2006-01-31
Sang-Hoon Kim DFI	Director of Finance/CFO	66	-

Director	Title	Age	Since
Ki-Ok Kim BRD	Director/Board Member	71	2006-01-31
Hak-Soo Lee BRD	Director/Board Member	70	2020-03-19
Min-Ee Kim BRD	Director/Board Member	40	-

Date	Insider	Type	Main position	Quantity	% Market Cap.
5/24/24	Sang-Hoon Kim	Others	Chief Financial Officer	404,000	2.1053%
5/19/24	Sang-Hoon Kim	Free	Chief Financial Officer	404,000	2.1053%

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Change	5-day change	1-year change	3-year change	Capi.($)
GENOLUTION INC.	-0.07%	-2.02%	-37.75%	-68.37%	16.49M
VERACYTE, INC.	-0.15%	+3.79%	+151.51%	+98.56%	4.72B
ADAPTIVE BIOTECHNOLOGIES CORPORATION	+3.71%	+8.83%	+120.60%	+201.98%	3.67B
IOVANCE BIOTHERAPEUTICS, INC.	+7.30%	+18.20%	+124.22%	-38.65%	2.23B
CAREDX, INC.	-1.51%	+39.35%	+233.45%	+285.35%	2.05B
BGI GENOMICS CO., LTD.	-5.50%	-0.75%	-29.67%	-37.76%	2.04B
MARAVAI LIFESCIENCES HOLDINGS, INC.	+2.12%	+18.88%	+197.94%	-41.99%	1.07B
SEEGENE, INC.	-2.39%	-1.55%	-10.78%	+35.95%	875M
HANGZHOU ALLTEST BIOTECH CO., LTD.	-4.16%	+6.17%	-34.21%	-11.74%	513M
CURIOX BIOSYSTEMS CO., LTD	-3.06%	-3.18%	-3.97%	-	476M
Average	-0.37%	+8.92%	+71.13%	+47.04%	1.77B
Weighted average by Cap.	+0.65%	+10.75%	+115.28%	+93.60%

	2024	2025
Net sales	7.14B 4.8M 4.19M 3.87M 3.57M 6.72M 462M 6.87M 46.25M 18.19M 226M 18.02M 17.63M 779M	9.4B 6.32M 5.53M 5.1M 4.7M 8.86M 609M 9.06M 60.96M 23.98M 298M 23.75M 23.23M 1.03B
Net income	-6.83B -4.59M -4.01M -3.7M -3.41M -6.43M -442M -6.57M -44.24M -17.4M -216M -17.24M -16.86M -745M	-11.64B -7.83M -6.84M -6.31M -5.82M -10.97M -754M -11.21M -75.47M -29.68M -369M -29.4M -28.76M -1.27B
Net Debt	-8.95B -6.02M -5.26M -4.85M -4.47M -8.43M -580M -8.62M -58.01M -22.82M -284M -22.6M -22.11M -977M	-3.89B -2.61M -2.28M -2.11M -1.94M -3.66M -252M -3.74M -25.19M -9.91M -123M -9.81M -9.6M -424M